logo
Plus   Neg
Share
Email

Sohu To Acquire Remaining Stake In Changyou In All Cash Deal

Chinese online media and gaming business Sohu.com Limited (SOHU) said it entered into a definitive agreement to acquire all shares of majority-owned unit Changyou.com (CYOU) that it does not already own in an all-cash transaction. The implying equity value of Changyou shares in the deal is about $579.0 million.

The companies said the deal is a 'going-private' transaction.

The merger is currently expected to close in the second quarter of 2020. If completed, the merger will result in Changyou becoming a privately-owned company, wholly owned directly and indirectly by Sohu.

At the effective time of the merger, Changyou shares will be cancelled and cease to exist, in exchange for the right to receive $5.40 in cash per share without interest. Each outstanding American depositary share will be cancelled in exchange for the right to receive $10.80 in cash without interest.

The merger consideration represents a premium of 82.4 percent to the closing price of the Changyou's ADSs on September 6, 2019, the last trading day prior to the company's announcement of its receipt of the "going-private" proposal.

Sohu, which owns over 90 percent of the voting power, intends to fund the merger primarily with debt financing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
Follow RTT
>